Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R C Bast

Showing results (291-300 of 299) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 299 results.
Oncogene|June 7, 2011
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathwaysD B Badgwell, Z Lu, K Le, et al.
Journal of the National Cancer Institute|October 16, 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markersD F Hayes, R C Bast, C E Desch, et al.
European Journal of Gynaecological Oncology|February 24, 2001
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGOP Bösze, R C Bast, A Berchuck, et al.
Gynecologic Oncology|August 25, 2001
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancerM L Donato, D M Gershenson, J T Wharton, et al.
Bone Marrow Transplantation|May 4, 2004
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantationM L Donato, A Aleman, R E Champlin, et al.
Bone Marrow Transplantation|June 13, 2000
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancerM L Donato, D Gershenson, C Ippoliti, et al.
Cancer Research|August 2, 2001
Genetic analysis of early- versus late-stage ovarian tumorsV Shridhar, J Lee, A Pandita, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 WorkshopM Nap, A Vitali, K Nustad, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and MedicineK Nustad, R C Bast, T J Brien, et al.
Pageof 30

Showing results (291-300 of 299) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 299 results.
Oncogene|June 7, 2011
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathwaysD B Badgwell, Z Lu, K Le, et al.
Journal of the National Cancer Institute|October 16, 1996
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markersD F Hayes, R C Bast, C E Desch, et al.
European Journal of Gynaecological Oncology|February 24, 2001
Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGOP Bösze, R C Bast, A Berchuck, et al.
Gynecologic Oncology|August 25, 2001
High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancerM L Donato, D M Gershenson, J T Wharton, et al.
Bone Marrow Transplantation|May 4, 2004
Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantationM L Donato, A Aleman, R E Champlin, et al.
Bone Marrow Transplantation|June 13, 2000
High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancerM L Donato, D Gershenson, C Ippoliti, et al.
Cancer Research|August 2, 2001
Genetic analysis of early- versus late-stage ovarian tumorsV Shridhar, J Lee, A Pandita, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 WorkshopM Nap, A Vitali, K Nustad, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1996
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and MedicineK Nustad, R C Bast, T J Brien, et al.
Pageof 30